Cencora’s senior director of manufacturer operations and data services, Ameer Ali, is raising the alarm over the scale of disruption that the pharmaceutical industry faces in transitioning to the 12-digit NDC format.
The FDA has issued a final rule requiring the entire healthcare industry to complete the shift to NDC-12 by March 2033, a deadline that industry insiders say should not be taken lightly.
Ali, who joined Cencora in 2015 to support Drug Supply Chain Security Act-related process implementations, has become one of the most prominent voices preparing the sector for this sweeping change.
His responsibilities at Cencora span both data exchange and barcode compliance, giving him a broad perspective on the operational complexity that NDC-12 will demand across the supply chain.
The NDC code underpins virtually every pharmaceutical transaction conducted in the United States, making the transition far more consequential than a straightforward labeling update.
Industry observers have described the shift as a “Y2K-level event,” a comparison that underscores just how deeply embedded the current NDC format is within healthcare IT infrastructure and business processes.
Ali presented at an HDA session focused on what organisations need to be doing now to prepare their EDI systems, back-office platforms, DSCSA frameworks, and packaging-line systems for the incoming format change.
The breadth of systems affected means that wholesalers, manufacturers, pharmacies, and healthcare providers will all need to audit and overhaul significant portions of their technology stacks well ahead of the 2033 deadline.
Experts in pharmaceutical logistics have consistently warned that leaving NDC-12 preparation until the final years before the deadline risks creating bottlenecks that could disrupt drug distribution across the country.
Cencora, as one of the largest pharmaceutical distribution companies in the United States, is positioned at the centre of this transition and is actively working to ensure its own systems and those of its manufacturing partners are ready for the change.
Ali’s work at the intersection of manufacturer operations and data services places him in a critical role as the industry maps out the technical and logistical steps needed to meet the FDA’s requirements.
The 2033 deadline may appear distant, but the scale of back-office transformation required means that organisations delaying their planning risk repeating the costly scrambles that characterised major compliance deadlines in the past.